Where artificial intelligence could reach healthcare first

Following our earlier comments on how artificial intelligence (AI) may support investment analysis, this article explores where artificial intelligence could reach healthcare first. In our view, innovation can drive meaningful change in healthcare. For example, healthcare systems hold large volumes of data that analysts can turn into useful information. In addition, pharmaceutical companies constantly look for ways to shorten long drug development timelines. Theoretically, AI could support more effective management across the industry. In other words, it may help deliver the right treatments, in the right quantities, to the right patients. However, AI adoption in healthcare remains early, and outcomes are uncertain.

Where artificial intelligence could reach healthcare first

• Research and development. AI could potentially help improve the success rates of medications in clinical trials. For example, researchers could use AI to screen candidate compounds before costly laboratory work begins. However, that process could take years, and results may vary.
• Clinical trials. Applying AI to logistics could speed up trials and improve efficiency. For instance, it could help companies find clinical sites able to enroll patients faster. It could also flag underperforming sites that need improvement.
• Commercial development. AI could help companies identify the physicians and specialists best placed to support a new product launch. As a result, it may reduce some obstacles to reaching the market. It could also help companies focus on the events most likely to build interest in a new medication. Of course, strict healthcare marketing rules still apply.
• Complementing human expertise. Every patient wants an accurate diagnosis, and AI may make a meaningful difference here. For example, AI assistance could help a physician assess a patient’s uncommon symptoms. In practice, providers may then reach better-informed conclusions. Even so, AI tools can make errors, so physician judgment remains essential.

Why progress may take time and face regulation

These areas could mark the first contact between AI and the sector. Even so, in our view the process will likely take time. Regulators, providers, and investors may evaluate progress continually to confirm whether AI delivers better results and economic benefits. Meanwhile, new rules could slow adoption or add costs. In our opinion, these capabilities appear likely to endure, although their pace and impact remain uncertain.

How to read early signals of adoption

Investors may find it useful to watch a few practical indicators. First, they can look for evidence in company results that AI tools shorten timelines or reduce costs. Next, they can follow how regulators respond to new tools and whether guidance becomes clearer over time. In addition, partnerships between technology firms and healthcare providers may show where demand is building. Above all, readers should treat early announcements with caution, because pilot projects do not always scale.

Data quality also matters. AI systems depend on the records they learn from, and incomplete or biased data can weaken results. Therefore, organizations may need to invest in better data management before they see benefits. Patient privacy adds another layer of responsibility. As a result, providers must protect sensitive information while they test new tools. In practice, this balance between innovation and privacy may shape how quickly each area develops.

What one industry participant has said

For instance, UnitedHealth Group has said that AI can help reduce the time needed to turn data into information. According to the company, this may allow a better understanding of the factors that affect a person’s health. When organizations implement it strategically, the technology may support better healthcare decisions and lower costs. However, implementation can be expensive, and benefits may not reach every organization. Finally, tracking where artificial intelligence could reach healthcare first may help readers follow how the sector evolves.

This article is for educational purposes only and is not investment advice or a recommendation regarding any security. Company references are illustrative, and the opinions expressed may not come to pass.